Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Accelr8 Technology Corp.
Accelr8 and BD Agree on Terms for Technology Development Program for theBACcel(TM) Rapid Diagnostics Platform
April 20th, 2008
Accelr8 Technology Corporation (Amex:AXK) announced that BD (Becton, Dickinson and Company) and Accelr8 have agreed in principle to terms for an agreement with respect to Accelr8's BACcel(TM) rapid bacterial diagnostic system. Under the contemplated agreement, BD will fund an 18-month milestone project starting April 1, 2008. BD will also have the option to license the technology for product development, manufacturing and commercialization for the clinical diagnosis of infectious diseases. The definitive agreement is expected to be signed before April 30, 2008. According to David Howson, Accelr8's president, "BD leads the industry in clinical...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-20)
|
